Skip to main content

Table 3 Characteristics of 48 patients with metastatic prostate cancer

From: Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer

Variables Median (range, mean ± SD)
Age (y) 70.5 (51–88, 71.33 ± 6.92)
Initial PSA (ng/mL) 82.16 (8.2–7285, 605.06 ± 1446.25)
Pathological Grade  
 Gleason Score ≤ 6 2 (4.2 %)
 Gleason Score = 7 14 (29.2 %)
 Gleason Score ≥ 8 32 (66.7 %)
Clinical T Stage  
 2 6 (12.5 %)
 3 27 (56.3 %)
 4 15 (31.3 %)
Clinical N Stage  
 0 21 (43.8 %)
 1 27 (56.3 %)
Clinical M Stage  
 0 13 (27.1 %)
 1 35 (72.9 %)
NLR 2.49 (0.84–10.56, 2.93 ± 1.66)